Background: In cancer patients with a large Body Surface Area, chemotherapy drug doses are often reduced, as studies have suggested that their pharmacokinetics may be altered. However, this strategy may result in underdosing obese patients.
introduction
Chemotherapy is widely used to treat, palliate, and downstage many cancers, and drug doses are usually calculated on the basis of individual patients' weight and height using Body Surface Area (BSA). However, a number of studies [1] [2] [3] [4] have suggested that the pharmacokinetics of anticancer agents are altered in patients with a high BSA, and as a result, chemotherapy drug doses given to such patients are often reduced. Although the guidelines for dose reductions are variable, a BSA of 2 m 2 is widely used as an upper limit: patients with a higher BSA being dosed as if their BSA was 2 m 2 . However, BSA does not distinguish between obese patients and tall thin patients. Therefore, a common way to define obesity is to calculate the patient's Body Mass Index (BMI) (in adults, a BMI > 25 is generally considered overweight and >30 obese).
Despite widespread use of dose reduction in the patients with a high BSA, the studies underpinning the concept used very small numbers of patients and the differences in pharmacokinetics (between patients with normal and high BSA) were difficult to identify and characterise. Some concern therefore remains that such dose reduction may not be appropriate.
Colorectal cancer is the third most common cancer worldwide [5] , and a disease in which chemotherapy is widely used, either in the adjuvant or advanced disease settings. A number of papers have looked at cohorts of patients with colorectal cancer and found associations between obesity and outcomes; although despite the large numbers of patients included in these studies, the results have not been consistent. For example, Dignam et al. [6] noted an association between obesity and increased recurrence and mortality in colon cancer patients, whereas Meyerhardt et al. [7] only saw this in females, and a further paper by some of the same authors [8] only found an association in male patients with rectal cancer. However, crucially, these studies did not take the drug doses received into consideration.
Recent trials run by the Medical Research Council (MRC) in colorectal cancer offered the opportunity to explore the impact of reducing doses in the obese. In these trials, a dose reduction for patients with a high BSA was recommended but not mandated. As a consequence, some participating centres chose to dose reduce patients and some chose not to. These trials therefore offer the opportunity to compare toxicity profiles and outcomes for those patients whose drug doses were reduced and those who were not.
The current study was therefore set up to:
1 Determine the proportion of patients receiving chemotherapy dose reductions as a consequence of their body size. 2 Investigate whether obese patients dosed according to their actual BSA were more likely to suffer from chemotherapyrelated toxic effects. 3 Explore whether dose reductions in obese patients resulted in shorter survival. A five-arm trial investigating various ways of scheduling two drugs (irinotecan and oxaliplatin) into treatment. The control arm (A) was 5-fluorouracil (5-FU), given in a modified de Gramont (MdG) schedule, followed by single-agent irinotecan on progression. Arm B was also MdG but followed by the combination of 5-FU and irinotecan on progression, and in arm C, patients started with the 5-FU + irinotecan (5-FU + Ir) combination. Arms D and E echoed arms B and C but with oxaliplatin instead of irinotecan. The randomisation was in the ratio of 2 : 1 : 1 : 1 : 1 for the control and the four experimental arms, respectively. Thus, two-thirds of the patients received 5-FU, one-sixth 5-FU + Ir, and onesixth 5-FU + oxaliplatin (5-FU + Ox) as first-line treatment. The study accrued 2135 patients from May 2000 to December 2003 and was published in 2007 [9] . Median age of patients was 64 years, 68% were male, and 42%, 50%, and 8% were performance status zero, one, and two, respectively.
2. FOCUS2. This trial built on the experience gained in FOCUS and was a 2 · 2 factorial trial of chemotherapy for elderly and/or frail patients. Two of the four arms used schedules used in FOCUS (5-FU followed by 5-FU + Ox and first-line 5-FU + Ox) and in the other two arms, 5-FU was replaced by capecitabine (Cap). Four hundred and fifty-nine patients were accrued from January 2004 to July 2006 and the preliminary results have been presented [10] . Median age of patients was 74 years, 62% were male, and 22%, 50%, and 28% were performance status zero, one, and two, respectively.
3. COIN. This trial compared continuous 5-FU + Ox (or OxCap) versus intermittent 5-FU + Ox (or OxCap), building on the results of a previous MRC trial [11] as well as a third arm in which cetuximab was added to continuous 5-FU + Ox/ OxCap. The trial accrued a total of 2445 patients from March 2005 to May 2008 [12, 13] . Median age of patients was 63 years, 65% were male, and 47%, 46%, and 7% were performance status zero, one, and two, respectively.
Detailed information on all three trials can be found in the corresponding results papers [9, 10, 12, 13] .
methods and statistics
To categorise the patients' weights, each patient's BMI was calculated from their reported height and weight and patients were grouped into one of three subgroups (BMI < 25 normal weight, BMI 25-29 overweight, or BMI 30+ obese).
In order to verify the dose reduction, each patient's BSA was also calculated and the dose of drug actually given to each patient at the first cycle was compared with the dose based on the calculated BSA. If the received doses of all of the drugs were within 5% of the calculated doses, the patient was considered to have received full doses. If the received dose of any of the drugs was <95% of the calculated dose, the patient was considered to have been dose reduced. This 5% cut-off is commonly recognised as an acceptable error margin and is therefore being used to ascertain if doses have been reduced or not. If the received dose of any of the drugs was >105% of the calculated dose, the patient was excluded from the analysis. The v 2 test for trend was used to test for a trend in the number of patients being dose reduced from normal weight through to obese. Based on the known toxic effects to the drugs, patients were considered to have experienced significant toxicity if grade 3 or 4 stomatitis, neutropenia, or diarrhoea (and peripheral neuropathy for those on oxaliplatin) was reported in the first 12 weeks from starting chemotherapy (in all three trials, patients were assessed at 12 weeks, as they could change regimen at that point). The proportion of obese dose-reduced and fully dosed patients experiencing toxicity were then compared using a test of proportions, and the v 2 test for trend was used to test for a trend in the number of fully dosed patients experiencing a grade 3 or 4 toxicity across the three BMI subgroups. The proportion of patients dose reduced and the proportion of fully dosed patients experiencing grade 3 or 4 toxicity were also compared by sex, age, and World Health Organisation performance status (WHO PS), to explore any confounding factors, and tested using the v 2 test for interaction. A backwards stepwise multiple logistic regression at the 5% level of significance was used to explore the factors that might be associated with (i) a dose reduction and (ii) grade 3 or 4 toxicity. All patients were included for the dose reduction analysis and only the fully dosed for toxicity. The overall survival of the obese dose-reduced patients was compared with that of those fully dosed to investigate whether obese dose-reduced patients might have received suboptimal treatment. Kaplan-Meier plots and the logrank test were used, and the hazard ratio (HR) and 95% confidence interval (CI) calculated. A multivariate Cox regression model was then used to assess the effect of BMI and dose status on patients' survival allowing for all possible confounding factors.
results

results from the FOCUS data
Of the 2135 patients in the FOCUS trial, 2075 (97%) had sufficient data to calculate their BMI, as well as information on drug doses received and toxicity experienced, but 18 patients have been excluded from the analysis as they received >105% of the calculated drug doses. The proportion of patients classified by their BMI as normal weight, overweight, and obese were 989 (48%), 717 (35%), and 351 (17%), respectively. Only, 38 (4%) patients with normal weight (BMI < 25) were dose reduced, but this proportion increased with increasing weight: overweight 62 (9%) and obese 111 (32%) (P < 0.001) ( Table 1 ). Overall, in those patients who were fully dosed, the proportion experiencing a grade 3 or 4 toxicity did not appear to be affected by their weight: normal 166/951 (17%), overweight 109/655 (17%), and obese 36/240 (15%) (P = 0.11) ( Table 2) , and the obese patients who were fully dosed did not appear to experience more toxicity than those who were dose reduced (P = 0.94).
results from the FOCUS2 data
In the FOCUS2 trial, 416 (91%) of the 459 patients in the trial had adequate data, but 36 have been excluded as they received increased doses of drugs, and the results echoed those seen in FOCUS. One hundred and seventy seven (46%) were classified as normal weight, 136 (36%) as overweight, and 67 (18%) as obese. A significant association was observed between increasing weight and the proportion of patients having a drug dose reduction: normal weight 12%, overweight 21%, and obese 60%, P < 0.001. However, there was no indication that, in the patients fully dosed, obese patients subsequently experienced more toxicity: normal weight 12%, overweight 9%, and of the 27 obese patients who were fully dosed only 1 was reported as having had a grade 3 or 4 toxicity. Neither was there evidence that the obese patients who were fully dosed experienced more toxicity: fully dosed 4%, dose reduced 13%, P = 0.22.
results from the COIN data
In the COIN trial, 2365 (97%) of the 2445 patients had data on treatment and toxicity, and 21 were excluded as they received increased doses. The data echo that of FOCUS and FOCUS2. The proportions of patients considered to be in the three weight categories were: normal weight 43%, overweight 38%, and obese 19%. A strong association was seen for reducing doses according to increasing weight: normal weight 3%, overweight 20%, and obese 70%, P < 0.001 (Table  1) . There was no increase in toxicity in those patients fully dosed: normal weight 27%, overweight 25%, and obese 22% (P = 0.16), and there was no evidence that obese patients experienced more toxicity if they were given full dose: fully dosed 22%, dose reduced 16%, P = 0.15 (Table 2) .
overall results
Because of the consistency in all three trials, an overall picture of the patterns of dose reductions and toxicity can be given. Thus, in a total of 4781 patients, 826 (17%) were dose reduced, and there was strong evidence to suggest that this was associated with their BMI category (P < 0.001), with only 88 (4%) normal weight patients having reductions, compared with 272 (16%) and 466 (54%) for overweight and obese patients, respectively (Table 1 ). There was some evidence to suggest that there was a trend in toxicity rates for those patients fully dosed and their BMI group (P = 0.035); however, this is not in the direction that might be expected (patients with a normal BMI appear to be experiencing more toxicity than obese patients: normal weight 21%, overweight 20%, and obese 17%). A comparison of toxicity between obese patients dose reduced and those fully dosed showed no evidence of a difference: fully dosed 17%, dose reduced 16%, P = 0.71 (Table 2) .
survival and progression-free survival
The overall survival of obese patients who were dose reduced compared with those who were fully dosed is shown in Figure 1 . This shows a slight improvement in overall survival for patients who were fully dosed, although this difference did Figure 2 .
confounding factors
In addition to reducing the drug doses for reasons of body size, patients will have had their drug doses reduced for a number of other reasons, and it is important to try and confirm that these factors were not biasing the results. A number of other possible confounding factors were explored: drug regimen, sex, age, and performance status. Table 3 shows that there were no systematic differences between the three BMI subgroups, and Table 4 shows the proportion of patients with dose reductions for these potentially confounding factors. There was some evidence to suggest an association between sex and the proportion of patients who were dose reduced (18% of men, 15% of women, P = 0.012), but there was no evidence of associations between age (P = 0.56) or WHO PS (P = 0.49) and the proportion of patients being dose reduced. Table 5 shows that there was strong evidence to suggest an association between sex and whether or not patients who were fully dosed had a grade 3 or 4 toxicity (24% of women, 18% of men, P < 0.001) and some evidence to suggest a trend across age groups (P = 0.026) and WHO PS (P = 0.05). However, the only subgroup where there appeared to be a lessening of toxicity with dose reduction was in patients receiving the 5-FU + Ox regimen (P = 0.0065).
multiple regression
A multivariable stepwise regression was undertaken to explore the associations between potential factors (age, sex, WHO PS, trial drug, BMI group, and BSA) and dose reduction, and also toxicity. There was evidence to suggest that patients were more likely to be dose reduced if they had a higher BMI, were in the FOCUS2 or COIN trials, and had a BSA ‡ 2.0 m 2 (all P < 0.001). In terms of toxicity (and for those patients fully dosed), female patients >55 years, with a WHO PS of one or two, who were receiving 5-FU + Ir or 5-FU + Ox (P < 0.001), were more likely to experience toxicity. When allowing for all other potential factors BMI, sex, and WHO PS showed a statistically significant association with overall survival (P < 0.001; 0.013; and <0.001, respectively).
discussion
Although chemotherapy drug dose reduction in patients with a high BSA is a widely accepted practice [14] , the evidence that drugs have different pharmacokinetic properties in such patients is based on a few small studies. However, in a number of recent MRC trials of chemotherapy in patients with advanced colorectal cancer, dose reduction was not mandatory, and the choice was left to local clinicians or centre policy, although, in the event, the data suggest that each centre and practice considered each patient separately rather than enforcing a strict policy. This has allowed the comparison of those obese patients who were dose reduced and those who were not (although of course this was not a randomised comparison). The results strongly suggest that, in all three trials considered, obese patients who were fully Figure 2 . Progression-free survival in obese (Body Mass Index 30+) patients (dose-reduced versus fully dosed patients).
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dosed according to their calculated BSA did not experience increased levels of toxicity. In addition, dose reduction in obese patients may have resulted in a slightly inferior survival time.
Is it now possible to recommend that all patients receive full doses? There may still be good reasons why clinicians feel individual patients need to have reduced drug doses. Indeed, in all three trials, a small proportion of patients with normal BMI received reduced doses, although, unfortunately, details of the reasons for dose-reducing patients were not routinely collected. It may have been because of their age, performance status, or co-morbidities, although all patients should have been of a certain fitness in order to be eligible for the particular trial. Nevertheless, we found no strong evidence that patients' age or performance status affected the proportion dose reduced. However, a smaller proportion of women were dose reduced, though the reasons for this are not obvious.
The aim of cancer chemotherapy is to maximise efficiency and minimise toxicity. Our results suggest that giving obese patients the full doses (based on their calculated BSA) results in similar levels of toxicity to non-obese patients. Nevertheless, a proportion of patients, in all BMI subgroups, do experience some severe toxicity, suggesting that perhaps these patients may be being over dosed. Sparreboom et al. [4] suggest that different drugs may need different methods of determining doses and a number of alternatives to BSA have been proposed, and indeed, some are already in use for specific drugs (e.g. Area Under the Curve for carboplatin), as in these specific cases BSA has been shown to be a poor surrogate for overall drug clearance. There is little evidence that for the majority of cancer drugs alternative ways of dosing are any better [15] , and thus, BSA appears to remain the gold standard. Our results are supported by a number of papers in colorectal cancer. Reviewing 1688 patients in a trial of postoperative fluorouracil-based chemotherapy and radiotherapy for stage II/III rectal cancer, all of whom received the full dose according to actual body weight, Meyerhardt et al. [8] reported that there was actually a lower overall rate of grade 3 or 4 leucopoenia (P = 0.04), neutropenia (P = 0.003), and stomatitis (P = 0.03) with increasing BMI. Meyerhardt et al. [7] also looked at 3438 patients with high-risk stage II/III colon cancer and concluded that obesity was not associated with any increase in chemotherapy-related toxicity.
The link between obesity, dose reduction, and outcomes has been investigated in other cancers. In breast cancer, Griggs et al. [16] carried out a retrospective cohort study involving 9672 women treated with doxorubicin and cyclophosphamide. The paper concluded that obese patients who had received full-dose chemotherapy were not at an increased risk of febrile neutropenia, and indeed, the authors inferred that severe obesity was in fact associated with a lower likelihood of febrile neutropenia. Rosner et al. [17] used data from 1435 women in the Cancer and Leukaemia Group B study 8541 that were treated with adjuvant chemotherapy for stage II breast cancer and found no significant differences in the patients that were dosed according to their actual body weight. Indeed, obese and overweight patients had a lower incidence of grade ‡3 toxicity.
In ovarian cancer, Wright et al. [18] observed that, in their study of 387 women treated with carboplatin and paclitaxel on the Gynecologic Oncology Group protocol 158, obese patients experienced less toxicity and the authors surmised that this may have been due to dose capping and thus receiving a suboptimal dose. Barrett et al. [19] , in an analysis of 1067 women in the SCOTROC trial, where all patients received full doses of carboplatin and taxane, saw no difference in PFS or overall survival between any of the BMI subgroups.
While we recognise that there will inevitably be a group of patients that will benefit from a dose reduction, we believe the results of our study reach the same conclusion as the review by Hunter et al. [14] who estimated that underdosing obese patients to avoid toxicity could be costing them months, if not years, of survival.
Nevertheless, our results must still be considered hypothesis generating, as our study suffers from the fact that it uses data collected for other purposes. Therefore, a prospective, and ideally randomised, study collecting all the relevant data, especially the reasons for dose reduction, and more accurate linking of dose and toxicity, is required to confirm these findings.
